New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
10:04 EDTQCORQuestcor weakness attributed to change in CDF funding
The Chronic Disease Fund, or CDF, indicates on its website that funding for Nephrotic Syndrome is currently closed for new enrollments. Questcor, whose Acthar gel is indicated for the treatment of Nephrotic Syndrome, is down over 6% to $49.48 in early trading. Reference Link
News For QCOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for QCOR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use